MX2024007883A - Compuestos de sulfonamida bifuncionales. - Google Patents

Compuestos de sulfonamida bifuncionales.

Info

Publication number
MX2024007883A
MX2024007883A MX2024007883A MX2024007883A MX2024007883A MX 2024007883 A MX2024007883 A MX 2024007883A MX 2024007883 A MX2024007883 A MX 2024007883A MX 2024007883 A MX2024007883 A MX 2024007883A MX 2024007883 A MX2024007883 A MX 2024007883A
Authority
MX
Mexico
Prior art keywords
bifunctional
sulfonamide compounds
compounds
formula
mlkl
Prior art date
Application number
MX2024007883A
Other languages
English (en)
Spanish (es)
Inventor
Jean- Marc Daniel GARNIER
Martin Brzozowski
Guillaume Laurent Lessene
Christopher Gardner
Wilhelmus Johannes Antonius Kersten
Original Assignee
Anaxis Pharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021904204A external-priority patent/AU2021904204A0/en
Application filed by Anaxis Pharma Pty Ltd filed Critical Anaxis Pharma Pty Ltd
Publication of MX2024007883A publication Critical patent/MX2024007883A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024007883A 2021-12-22 2022-12-22 Compuestos de sulfonamida bifuncionales. MX2024007883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2021904204A AU2021904204A0 (en) 2021-12-22 Bifunctional sulphonamide compounds
PCT/AU2022/051575 WO2023115149A1 (en) 2021-12-22 2022-12-22 Bifunctional sulphonamide compounds

Publications (1)

Publication Number Publication Date
MX2024007883A true MX2024007883A (es) 2024-09-23

Family

ID=86900865

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007883A MX2024007883A (es) 2021-12-22 2022-12-22 Compuestos de sulfonamida bifuncionales.

Country Status (9)

Country Link
US (1) US20250074891A1 (https=)
EP (1) EP4452966A4 (https=)
JP (1) JP2025501765A (https=)
KR (1) KR20240151737A (https=)
CN (1) CN119013268A (https=)
AU (1) AU2022420983A1 (https=)
CA (1) CA3241593A1 (https=)
MX (1) MX2024007883A (https=)
WO (1) WO2023115149A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096550A1 (en) * 2023-10-31 2025-05-08 Twine Therapeutics, Inc. Methods of treating cardiomyopathy
WO2025155642A1 (en) * 2024-01-21 2025-07-24 The Regents Of The University Of California Dcaf16-based covalent handle for the rational design of monovalent degraders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948544A1 (en) * 2014-05-15 2015-11-19 Catalyst Therapeutics Pty Ltd Methods for inhibiting necroptosis
CA2976121A1 (en) * 2015-02-10 2016-08-18 Catalyst Therapeutics Pty Ltd Inhibitors of necroptosis
WO2018192416A1 (en) * 2017-04-17 2018-10-25 National Institute Of Biological Sciences, Beijing Treating Male Senescence
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
DK4168401T3 (da) * 2020-06-19 2026-04-13 Anaxis Pharma Pty Ltd Sulfonamidforbindelser

Also Published As

Publication number Publication date
US20250074891A1 (en) 2025-03-06
WO2023115149A1 (en) 2023-06-29
CA3241593A1 (en) 2023-06-29
CN119013268A (zh) 2024-11-22
AU2022420983A1 (en) 2024-07-04
JP2025501765A (ja) 2025-01-23
EP4452966A4 (en) 2025-12-17
EP4452966A1 (en) 2024-10-30
KR20240151737A (ko) 2024-10-18

Similar Documents

Publication Publication Date Title
MX2024001824A (es) Compuestos heterociclicos y metodos de uso.
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
MX2020009517A (es) Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
CA3241619A1 (en) Bifunctional arylsulphonamide compounds
MY195782A (en) Carbamoyloxymethyl Triazole Cyclohexyl Acids as LPA Antagonists
MX2023006606A (es) Derivados biciclicos.
MX2024007883A (es) Compuestos de sulfonamida bifuncionales.
BR112022025732A2 (pt) Compostos de sulfonamida
CO5650246A2 (es) Derivados de indazolil(indolil)maleimida sustituidos como inhibidores de cinasa
MX2021007540A (es) Derivados biciclicos.
NO20083207L (no) Inhibitorer av IAP
MA39881B1 (fr) Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1
CY1116628T1 (el) Ενωσεις σπειρο-οξινδολιου και χρηση αυτων ως θεραπευτικοι παραγοντες
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
SA522431429B1 (ar) Sting مركبات كبيرة الحلقات كمساعِدات وطرق واستخداماتها
GEAP202516632A (en) Heteroaryl compounds for the treatment of pain
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MX2020007521A (es) Inhibidores de pi4kiii.
MX2022011194A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
MX2022006281A (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
GEAP202516765A (en) Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.
MX2025008454A (es) Inhibidores de mptp